ctDNA as a biomarker of progression in oesophageal adenocarcinoma

BACKGROUND: The incidence of oesophageal adenocarcinoma (OAC) is rapidly increasing and despite improvements in treatment, the 5-year survival rate remains poor. Prognostic biomarkers that address the genomic heterogeneity in this highly complex disease will aid the development of precision therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonazzi, V.F., Aoude, L.G., Brosda, S., Lonie, J.M., Patel, K., Bradford, J.J., Koufariotis, L.T., Wood, S., Smithers, B. Mark, Waddell, N., Barbour, A.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271467/
https://www.ncbi.nlm.nih.gov/pubmed/35798469
http://dx.doi.org/10.1016/j.esmoop.2022.100452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271467/
https://www.ncbi.nlm.nih.gov/pubmed/35798469
http://dx.doi.org/10.1016/j.esmoop.2022.100452

Ejemplares similares